VEGFA and metastatic colorectal cancer: The chimeric monoclonal immunoglobulin G3 (IgG3) antibody directed against soluble circulating vascular endothelial growth factor-A (VEGF-A), bevacizumab, gained a prominent role in different solid tumor types, such as in breast, ovarian, kidney, and lung cancers [1,2,3,4] since its introduction as a first line therapeutic option for metastatic colorectal cancer (mCRC) patients [5].